JP6325985B2 - 固体媒体上に貯蔵された生物学的サンプル中の脂肪酸の安定化および分析 - Google Patents
固体媒体上に貯蔵された生物学的サンプル中の脂肪酸の安定化および分析 Download PDFInfo
- Publication number
- JP6325985B2 JP6325985B2 JP2014551485A JP2014551485A JP6325985B2 JP 6325985 B2 JP6325985 B2 JP 6325985B2 JP 2014551485 A JP2014551485 A JP 2014551485A JP 2014551485 A JP2014551485 A JP 2014551485A JP 6325985 B2 JP6325985 B2 JP 6325985B2
- Authority
- JP
- Japan
- Prior art keywords
- fatty acids
- fatty acid
- solid
- paper
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000007787 solid Substances 0.000 title claims description 194
- 235000014113 dietary fatty acids Nutrition 0.000 title claims description 183
- 239000000194 fatty acid Substances 0.000 title claims description 183
- 150000004665 fatty acids Chemical class 0.000 title claims description 183
- 229930195729 fatty acid Natural products 0.000 title claims description 182
- 239000012472 biological sample Substances 0.000 title claims description 13
- 238000004458 analytical method Methods 0.000 title description 4
- 238000011105 stabilization Methods 0.000 title description 4
- 230000006641 stabilisation Effects 0.000 title description 2
- 210000004369 blood Anatomy 0.000 claims description 171
- 239000008280 blood Substances 0.000 claims description 171
- 239000011159 matrix material Substances 0.000 claims description 144
- 238000000034 method Methods 0.000 claims description 121
- 239000000523 sample Substances 0.000 claims description 90
- 239000000356 contaminant Substances 0.000 claims description 77
- 239000003963 antioxidant agent Substances 0.000 claims description 71
- 235000006708 antioxidants Nutrition 0.000 claims description 71
- 239000002738 chelating agent Substances 0.000 claims description 68
- 239000000203 mixture Substances 0.000 claims description 64
- 230000003078 antioxidant effect Effects 0.000 claims description 62
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 56
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims description 43
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical group CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 43
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 43
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims description 43
- 239000011521 glass Substances 0.000 claims description 41
- 150000002632 lipids Chemical class 0.000 claims description 37
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 36
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 32
- 239000000741 silica gel Substances 0.000 claims description 30
- 229910002027 silica gel Inorganic materials 0.000 claims description 30
- 229960005070 ascorbic acid Drugs 0.000 claims description 27
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 24
- 235000010323 ascorbic acid Nutrition 0.000 claims description 23
- 239000011668 ascorbic acid Substances 0.000 claims description 23
- 229920001410 Microfiber Polymers 0.000 claims description 22
- 239000003658 microfiber Substances 0.000 claims description 22
- 210000002381 plasma Anatomy 0.000 claims description 21
- 230000000087 stabilizing effect Effects 0.000 claims description 20
- 235000020256 human milk Nutrition 0.000 claims description 17
- 210000004251 human milk Anatomy 0.000 claims description 17
- 150000004671 saturated fatty acids Chemical group 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 14
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 11
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 8
- -1 polytetrafluoroethylene Polymers 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 8
- 239000004255 Butylated hydroxyanisole Substances 0.000 claims description 7
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 7
- 229940043253 butylated hydroxyanisole Drugs 0.000 claims description 7
- 210000003296 saliva Anatomy 0.000 claims description 7
- 210000000582 semen Anatomy 0.000 claims description 7
- 210000002700 urine Anatomy 0.000 claims description 7
- 239000000919 ceramic Substances 0.000 claims description 6
- 239000011152 fibreglass Substances 0.000 claims description 6
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 6
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 6
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 6
- 230000003247 decreasing effect Effects 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 2
- 239000003344 environmental pollutant Substances 0.000 claims 2
- 231100000719 pollutant Toxicity 0.000 claims 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 56
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 29
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 29
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 29
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 29
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 29
- 229940090949 docosahexaenoic acid Drugs 0.000 description 28
- 238000003860 storage Methods 0.000 description 24
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 210000001124 body fluid Anatomy 0.000 description 19
- 239000010839 body fluid Substances 0.000 description 19
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 14
- 229940012843 omega-3 fatty acid Drugs 0.000 description 14
- 239000002253 acid Substances 0.000 description 12
- 238000004817 gas chromatography Methods 0.000 description 11
- 229920000298 Cellophane Polymers 0.000 description 10
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 10
- 241000282414 Homo sapiens Species 0.000 description 9
- 235000003441 saturated fatty acids Nutrition 0.000 description 9
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 8
- 239000006014 omega-3 oil Substances 0.000 description 8
- 239000003223 protective agent Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000010898 silica gel chromatography Methods 0.000 description 7
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 7
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 229910052782 aluminium Inorganic materials 0.000 description 6
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 6
- 238000011109 contamination Methods 0.000 description 6
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 239000004816 latex Substances 0.000 description 6
- 229920000126 latex Polymers 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 239000011347 resin Chemical class 0.000 description 6
- 229920005989 resin Chemical class 0.000 description 6
- 239000002211 L-ascorbic acid Substances 0.000 description 5
- 235000000069 L-ascorbic acid Nutrition 0.000 description 5
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 229910052742 iron Inorganic materials 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 150000002825 nitriles Chemical class 0.000 description 5
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 229920000573 polyethylene Polymers 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 238000007605 air drying Methods 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 235000021323 fish oil Nutrition 0.000 description 4
- 239000011888 foil Substances 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 241001507939 Cormus domestica Species 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 235000004626 essential fatty acids Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 150000002617 leukotrienes Chemical class 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 210000001179 synovial fluid Anatomy 0.000 description 3
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 3
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 3
- 238000005809 transesterification reaction Methods 0.000 description 3
- MHVJRKBZMUDEEV-UHFFFAOYSA-N (-)-ent-pimara-8(14),15-dien-19-oic acid Natural products C1CCC(C(O)=O)(C)C2C1(C)C1CCC(C=C)(C)C=C1CC2 MHVJRKBZMUDEEV-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 230000005961 cardioprotection Effects 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- 239000001307 helium Substances 0.000 description 2
- 229910052734 helium Inorganic materials 0.000 description 2
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- MXYATHGRPJZBNA-KRFUXDQASA-N isopimaric acid Chemical compound [C@H]1([C@](CCC2)(C)C(O)=O)[C@@]2(C)[C@H]2CC[C@@](C=C)(C)CC2=CC1 MXYATHGRPJZBNA-KRFUXDQASA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229960003330 pentetic acid Drugs 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MHVJRKBZMUDEEV-APQLOABGSA-N (+)-Pimaric acid Chemical compound [C@H]1([C@](CCC2)(C)C(O)=O)[C@@]2(C)[C@H]2CC[C@](C=C)(C)C=C2CC1 MHVJRKBZMUDEEV-APQLOABGSA-N 0.000 description 1
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BTXXTMOWISPQSJ-UHFFFAOYSA-N 4,4,4-trifluorobutan-2-one Chemical compound CC(=O)CC(F)(F)F BTXXTMOWISPQSJ-UHFFFAOYSA-N 0.000 description 1
- MXYATHGRPJZBNA-UHFFFAOYSA-N 4-epi-isopimaric acid Natural products C1CCC(C(O)=O)(C)C2C1(C)C1CCC(C=C)(C)CC1=CC2 MXYATHGRPJZBNA-UHFFFAOYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- BQACOLQNOUYJCE-FYZZASKESA-N Abietic acid Natural products CC(C)C1=CC2=CC[C@]3(C)[C@](C)(CCC[C@@]3(C)C(=O)O)[C@H]2CC1 BQACOLQNOUYJCE-FYZZASKESA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000016444 Benign adult familial myoclonic epilepsy Diseases 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 240000000385 Brassica napus var. napus Species 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- RWWVEQKPFPXLGL-ONCXSQPRSA-N L-Pimaric acid Chemical compound [C@H]1([C@](CCC2)(C)C(O)=O)[C@@]2(C)[C@H]2CC=C(C(C)C)C=C2CC1 RWWVEQKPFPXLGL-ONCXSQPRSA-N 0.000 description 1
- RWWVEQKPFPXLGL-UHFFFAOYSA-N Levopimaric acid Natural products C1CCC(C(O)=O)(C)C2C1(C)C1CC=C(C(C)C)C=C1CC2 RWWVEQKPFPXLGL-UHFFFAOYSA-N 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 239000003918 blood extract Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960000958 deferoxamine Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 208000016427 familial adult myoclonic epilepsy Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000004133 fatty acid degradation Effects 0.000 description 1
- 125000005313 fatty acid group Chemical group 0.000 description 1
- 235000020988 fatty fish Nutrition 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940075525 iron chelating agent Drugs 0.000 description 1
- 239000000797 iron chelating agent Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000036630 mental development Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-K nitrilotriacetate(3-) Chemical compound [O-]C(=O)CN(CC([O-])=O)CC([O-])=O MGFYIUFZLHCRTH-UHFFFAOYSA-K 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 229940033080 omega-6 fatty acid Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002530 phenolic antioxidant Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 229910001428 transition metal ion Inorganic materials 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150015—Source of blood
- A61B5/15003—Source of blood for venous or arterial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150206—Construction or design features not otherwise provided for; manufacturing or production; packages; sterilisation of piercing element, piercing device or sampling device
- A61B5/150305—Packages specially adapted for piercing devices or blood sampling devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150358—Strips for collecting blood, e.g. absorbent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150755—Blood sample preparation for further analysis, e.g. by separating blood components or by mixing
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K15/00—Anti-oxidant compositions; Compositions inhibiting chemical change
- C09K15/04—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds
- C09K15/20—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds containing nitrogen and oxygen
- C09K15/22—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds containing nitrogen and oxygen containing an amide or imide moiety
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B5/00—Preserving by using additives, e.g. anti-oxidants
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B5/00—Preserving by using additives, e.g. anti-oxidants
- C11B5/0007—Organic substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/36—Embedding or analogous mounting of samples
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/50—Conditioning of the sorbent material or stationary liquid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/493—Physical analysis of biological material of liquid biological material urine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
- F04C—ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS; ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT PUMPS
- F04C2270/00—Control; Monitoring or safety arrangements
- F04C2270/04—Force
- F04C2270/042—Force radial
- F04C2270/0421—Controlled or regulated
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Surgery (AREA)
- Medical Informatics (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Ecology (AREA)
- Manufacturing & Machinery (AREA)
- Diabetes (AREA)
- Materials Engineering (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Sampling And Sample Adjustment (AREA)
- Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012900110 | 2012-01-11 | ||
| AU2012900110A AU2012900110A0 (en) | 2012-01-11 | Methods and mediums for stabilising fatty acids | |
| PCT/AU2013/000021 WO2013104025A1 (en) | 2012-01-11 | 2013-01-11 | Stabilising and analysing fatty acids in a biological sample stored on solid media |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015503756A JP2015503756A (ja) | 2015-02-02 |
| JP2015503756A5 JP2015503756A5 (enExample) | 2016-03-03 |
| JP6325985B2 true JP6325985B2 (ja) | 2018-05-16 |
Family
ID=48780974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014551485A Expired - Fee Related JP6325985B2 (ja) | 2012-01-11 | 2013-01-11 | 固体媒体上に貯蔵された生物学的サンプル中の脂肪酸の安定化および分析 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9645132B2 (enExample) |
| EP (1) | EP2802867B1 (enExample) |
| JP (1) | JP6325985B2 (enExample) |
| KR (1) | KR102071733B1 (enExample) |
| CN (1) | CN104254775B (enExample) |
| AP (1) | AP2014007862A0 (enExample) |
| BR (1) | BR112014017226B1 (enExample) |
| HK (1) | HK1203609A1 (enExample) |
| MX (1) | MX355406B (enExample) |
| NZ (1) | NZ628481A (enExample) |
| PH (1) | PH12014501589A1 (enExample) |
| RU (1) | RU2639455C2 (enExample) |
| WO (1) | WO2013104025A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108872404A (zh) * | 2017-05-09 | 2018-11-23 | 中国科学院上海生命科学研究院 | 超长链饱和脂肪酸或其检测试剂在代谢综合征患病风险预测中的应用 |
| EP3803321A4 (en) * | 2018-05-30 | 2022-01-19 | University Of South Australia | DEVICES AND METHODS FOR COLLECTING AND STORING LIQUID SAMPLES FOR ANALYSIS |
| CN110007040A (zh) * | 2019-03-12 | 2019-07-12 | 广西医科大学 | 一种关节腔内外源kgn含量测定方法 |
| RU2758932C1 (ru) * | 2020-07-17 | 2021-11-03 | Федеральное государственное бюджетное учреждение науки Федеральный исследовательский центр комплексного изучения Арктики имени академика Н.П. Лаверова Уральского отделения Российской академии наук (ФГБУН ФИЦКИА УрО РАН) | Способ измерения массовой концентрации метиловых эфиров жирных кислот в биологических средах методом газожидкостной хроматографии |
| KR102194995B1 (ko) | 2020-09-16 | 2020-12-28 | 장혜란 | 진단을 위한 개선된 건조체액의 안정화 조성물 및 이의 응용방법 |
| KR102541967B1 (ko) | 2020-12-08 | 2023-06-12 | 한국화학연구원 | 플라스틱 분해 미생물 스크리닝 배지 및 이의 제조방법 |
| KR20220082143A (ko) | 2020-12-09 | 2022-06-17 | 충남대학교산학협력단 | 노면온도표시를 위한 감온변색 도료 조성물 및 이를 이용한 노면온도표시선의 시공방법 |
| GB2619714B (en) * | 2022-06-13 | 2025-03-26 | Terex Gb Ltd | Method and device for installing a shaft in a material processing apparatus |
| CN115184114A (zh) * | 2022-07-18 | 2022-10-14 | 脂谱生物科技(上海)有限公司 | 一种具有抗菌涂层的中长链脂肪酸保存试纸及其制备方法 |
| CN115308078B (zh) * | 2022-08-09 | 2024-04-02 | 上海海洋大学 | 一种柔鱼类不同组织脂肪酸质量分数的测定方法 |
| WO2025187102A1 (ja) * | 2024-03-05 | 2025-09-12 | 株式会社 食機能探索研究所 Babilon | 赤血球捕集用濾紙 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1271568A (enExample) | 1959-07-30 | 1962-01-19 | Shell Int Research | |
| JPS5246838B2 (enExample) * | 1973-10-18 | 1977-11-28 | ||
| US6627226B2 (en) * | 1988-10-05 | 2003-09-30 | Whatman, Inc. | Dry solid medium for storage and analysis of genetic material |
| WO1990003959A1 (en) | 1988-10-05 | 1990-04-19 | The Flinders University Of South Australia | Solid medium and method for dna storage |
| US5116629A (en) * | 1990-10-24 | 1992-05-26 | General Mills, Inc. | Processed meat products containing fish oils stabilized with fructose |
| JP3177658B2 (ja) * | 1991-03-25 | 2001-06-18 | 東ソー株式会社 | 生体試料用濾紙 |
| US5234702A (en) * | 1992-03-19 | 1993-08-10 | Abbott Laboratories | Antioxidant system for powdered nutritional products |
| WO1996011406A1 (en) * | 1994-10-07 | 1996-04-18 | Flinders Technologies Pty. Ltd. | Apparatus and method for storage, purification or reaction and processing of a biopolymer |
| DE96915910T1 (de) * | 1995-06-07 | 2004-04-22 | Whatman Plc, Maidstone | Trockenes festes medium zur lagerung und analyse von genetischem material |
| US5728663A (en) * | 1996-07-02 | 1998-03-17 | Johnson & Johnson Consumer Products, Inc. | Clear, colorless soap bar with superior mildness, lathering and discolorization resistence |
| US6852289B2 (en) | 1996-10-02 | 2005-02-08 | Saftest, Inc. | Methods and apparatus for determining analytes in various matrices |
| JP3380230B2 (ja) * | 1998-09-02 | 2003-02-24 | アークレイ株式会社 | 血液の保存方法およびそれに用いる血液保存用具 |
| US6746841B1 (en) * | 1999-04-14 | 2004-06-08 | Whatman Inc. | FTA- coated media for use as a molecular diagnostic tool |
| US6420332B1 (en) * | 1998-12-23 | 2002-07-16 | Joseph J. Simpson | Blood and organic stain remover |
| US6673763B1 (en) * | 1999-09-24 | 2004-01-06 | Novozymes A/S | Particles for liquid compositions |
| DE19950066A1 (de) * | 1999-10-16 | 2001-04-26 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit einem Gehalt an Tulobuterol-hydrochlorid zur Verabreichung des Bronchodilatators Tulobuterol über die Haut |
| US6602718B1 (en) * | 2000-11-08 | 2003-08-05 | Becton, Dickinson And Company | Method and device for collecting and stabilizing a biological sample |
| US20050205840A1 (en) * | 2003-10-03 | 2005-09-22 | Farneth William E | Oxygen scavenging compositions and methods of use |
| DE602005016402D1 (de) * | 2004-05-24 | 2009-10-15 | Genvault Corp | Stabile lagerung von protein und stabile lagerung von nukleinsäure in wiedergewinnbarer form |
| CA2613631A1 (en) * | 2005-06-23 | 2007-01-04 | Spherics, Inc. | Improved dosage forms for movement disorder treatment |
| JP4942380B2 (ja) * | 2005-12-02 | 2012-05-30 | 月桂冠株式会社 | カルボン酸のアルキルエステル化方法及びキット |
| WO2009034124A1 (en) * | 2007-09-12 | 2009-03-19 | Novozymes A/S | Omega-3 stabilisation towards oxidation |
| US20100272875A1 (en) * | 2009-04-24 | 2010-10-28 | Monsanto Technology Llc | Omega-3 enriched cereal, granola, and snack bars |
| EP2338874A1 (en) * | 2009-12-16 | 2011-06-29 | Bracco Imaging S.p.A | Process for the preparation of chelated compounds |
| WO2011113043A2 (en) * | 2010-03-12 | 2011-09-15 | University Of South Florida | Sample storage for molecular and immunological detection |
| PL2575795T3 (pl) * | 2010-05-26 | 2020-06-01 | Kerecis Ehf | STABILIZOWANY PREPARAT ZAWIERAJĄCY KWASY TŁUSZCZOWE OMEGA-3 ORAZ ZASTOSOWANIE KWASÓW TŁUSZCZOWYCH DO PIELĘGNACJI SKÓRY l/LUB PIELĘGNACJI RAN |
| CN107202727B (zh) * | 2010-07-14 | 2020-12-22 | 恰根有限公司 | 用于分离和/或纯化生物分子的装置 |
| US9040675B2 (en) * | 2012-04-30 | 2015-05-26 | General Electric Company | Formulations for nucleic acid stabilization on solid substrates |
-
2013
- 2013-01-11 NZ NZ628481A patent/NZ628481A/en not_active IP Right Cessation
- 2013-01-11 EP EP13736428.7A patent/EP2802867B1/en active Active
- 2013-01-11 KR KR1020147022402A patent/KR102071733B1/ko not_active Expired - Fee Related
- 2013-01-11 RU RU2014132765A patent/RU2639455C2/ru active
- 2013-01-11 AP AP2014007862A patent/AP2014007862A0/xx unknown
- 2013-01-11 WO PCT/AU2013/000021 patent/WO2013104025A1/en not_active Ceased
- 2013-01-11 JP JP2014551485A patent/JP6325985B2/ja not_active Expired - Fee Related
- 2013-01-11 HK HK15103828.5A patent/HK1203609A1/xx unknown
- 2013-01-11 MX MX2014008495A patent/MX355406B/es active IP Right Grant
- 2013-01-11 CN CN201380012298.1A patent/CN104254775B/zh not_active Expired - Fee Related
- 2013-01-11 US US14/371,664 patent/US9645132B2/en not_active Expired - Fee Related
- 2013-01-11 BR BR112014017226-9A patent/BR112014017226B1/pt not_active IP Right Cessation
-
2014
- 2014-07-10 PH PH12014501589A patent/PH12014501589A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140136924A (ko) | 2014-12-01 |
| JP2015503756A (ja) | 2015-02-02 |
| MX2014008495A (es) | 2015-04-16 |
| EP2802867A1 (en) | 2014-11-19 |
| MX355406B (es) | 2018-04-18 |
| WO2013104025A1 (en) | 2013-07-18 |
| PH12014501589B1 (en) | 2014-10-20 |
| CN104254775B (zh) | 2017-07-21 |
| BR112014017226B1 (pt) | 2021-11-30 |
| PH12014501589A1 (en) | 2014-10-20 |
| KR102071733B1 (ko) | 2020-01-30 |
| EP2802867A4 (en) | 2016-01-06 |
| EP2802867B1 (en) | 2022-08-03 |
| CN104254775A (zh) | 2014-12-31 |
| US9645132B2 (en) | 2017-05-09 |
| NZ628481A (en) | 2016-11-25 |
| AU2013209278A1 (en) | 2014-08-28 |
| RU2014132765A (ru) | 2016-02-27 |
| BR112014017226A2 (pt) | 2020-10-27 |
| HK1203609A1 (en) | 2015-10-30 |
| RU2639455C2 (ru) | 2017-12-21 |
| US20150027208A1 (en) | 2015-01-29 |
| AP2014007862A0 (en) | 2014-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6325985B2 (ja) | 固体媒体上に貯蔵された生物学的サンプル中の脂肪酸の安定化および分析 | |
| Colpo et al. | Brazilian nut consumption by healthy volunteers improves inflammatory parameters | |
| Ren et al. | Total serum fatty acid analysis by GC-MS: assay validation and serum sample stability | |
| Christie et al. | Lipid analysis: isolation, separation, identification and lipidomic analysis | |
| Geppert et al. | Docosahexaenoic acid supplementation in vegetarians effectively increases omega‐3 index: a randomized trial | |
| Delmonte et al. | Evaluation of gas chromatographic methods for the determination of trans fat | |
| Hammond | Chromatography for the Analysis of Lipids | |
| Ma et al. | Relation of plasma phospholipid and cholesterol ester fatty acid composition to carotid artery intima-media thickness: the Atherosclerosis Risk in Communities (ARIC) Study | |
| Véricel et al. | Moderate oral supplementation with docosahexaenoic acid improves platelet function and oxidative stress in type 2 diabetic patients | |
| Ma et al. | The effect of heating on the formation of 4-hydroxy-2-hexenal and 4-hydroxy-2-nonenal in unsaturated vegetable oils: Evaluation of oxidation indicators | |
| Morera et al. | Triacylglycerol markers of mature human milk | |
| Escolano-Margarit et al. | Effects of fish oil supplementation on the fatty acid profile in erythrocyte membrane and plasma phospholipids of pregnant women and their offspring: a randomised controlled trial | |
| Brotas et al. | Determination, through derivatization and GC-MS analysis, of Omega-3 and Omega-6 fatty acids in fish oil capsules sold in Salvador, Bahia | |
| Moldovan et al. | Gas chromatographic and mass spectrometric methods for the characterisation of long-chain fatty acids: Application to wool wax extracts | |
| JP2015503756A5 (enExample) | ||
| KR20180100915A (ko) | 민감도 및 특이성이 향상된 지방산 분석 방법 | |
| Harlina et al. | Effects of galangal extract on lipid oxidation, antioxidant activity and fatty acid profiles of salted duck eggs | |
| Bayraklı | A study on fatty acid composition and quality indicators of anchovy (Engraulis encrasicolus) oils from different factories | |
| Pupillo et al. | Short-term stability of whole blood polyunsaturated fatty acid content on filter paper during storage at− 28 C | |
| Magnusardottir et al. | Effects of storage time and added antioxidant on fatty acid composition of red blood cells at− 20° C | |
| Benner Jr et al. | Standard Reference Material (SRM) 2378 fatty acids in frozen human serum. Certification of a clinical SRM based on endogenous supplementation of polyunsaturated fatty acids | |
| del Carmen García-Martínez et al. | Lipid stability in powdered infant formula stored at ambient temperatures | |
| Mensink | Effects of products made from a high-palmitic acid, trans-free semiliquid fat or a high-oleic acid, low-trans semiliquid fat on the serum lipoprotein profile and on C-reactive protein concentrations in humans | |
| Gao et al. | Comparation of oxylipin profiles as well as their substrates and synthetic enzymes transcriptional expression between marine fish Larimichthys crocea and freshwater fish Oncorhynchus mykiss | |
| AU2013209278B2 (en) | Stabilising and analysing fatty acids in a biological sample stored on solid media |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20150209 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150209 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160108 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160108 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20161027 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161108 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170208 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170711 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171005 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180403 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180413 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6325985 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |